Postpayment Service-Specific Probe Results for Drugs and Biological Services: Ranibizumab (Lucentis) for April through June 2021

Postpayment Service-Specific Probe Results for Drugs and Biological Services: Ranibizumab (Lucentis) in North Carolina, South Carolina, Virginia and West Virginia for April through June 2021

Palmetto GBA performed service-specific postpayment probe review on HCPCS Code J2778 — Ranibizumab (Lucentis). This edit was set in North Carolina, South Carolina, Virginia and West Virginia. The results for the probe review, for claims processed April through June 2021, are presented here.

Cumulative Results 
A total of 426 claims were reviewed, with 36 of the claims either completely or partially denied, resulting in an overall claim denial rate of 8.45 percent. The total dollars reviewed was $780,893.26, of which $62,595.55 was denied, resulting in a charge denial rate of 8.02 percent. Overall, there were a total of 35 auto-denied claims in the region. 

North Carolina Results
A total of 180 claims were reviewed, with 19 of the claims either completely or partially denied. This resulted in a claim denial rate of 10.56 percent. The total dollars reviewed was $324,006.19, of which $28,045.61 was denied, resulting in a charge denial rate of 8.66 percent. The top denial reasons were identified, and number of occurrences based on dollars denied are:

South Carolina Results
A total of 65 claims were reviewed, with none of the claims denied. This resulted in a claim denial rate of zero percent. The total dollars reviewed was $118,327.79, of which $0.00 was denied, resulting in a charge denial rate of zero percent. There were no denial reasons identified.

Virginia Results
A total of 137 claims were reviewed, with 17 of the claims either completely or partially denied. This resulted in a claim denial rate of 12.41 percent. The total dollars reviewed was $250,499.20, of which $34,549.94 was denied, resulting in a charge denial rate of 13.79 percent. The top denial reasons were identified, and number of occurrences based on dollars denied are:

West Virginia Results
A total of 44 claims were reviewed, with none of the claims either completely or partially denied. This resulted in a claim denial rate of zero percent. The total dollars reviewed was $88,060.08, of which $0.00 was denied, resulting in a charge denial rate of zero percent. There were no denial reasons identified.

Denial Reasons and Prevention Recommendations

NOTMN — Payer Deems the Information Submitted Does Not Support the Medical Necessity of the Services Billed

• Ensure that all documentation to support medical necessity of the service billed is submitted for review. This includes original chart notes and any diagnostic, radiological or laboratory results.
• Verify that documentation to support the level of service billed is included. Please refer to applicable LCDs, NCDs, and Coverage Articles for documentation requirements.
   

NOSIG — Documentation Lacks the Necessary Provider's Signature

• Verify that all documentation is legibly signed by the rendering physician or nonphysician practitioner
• Verify that electronic signature meets the CMS signature requirements as listed in the article Medicare Medical Records: Signature Requirements, Acceptable and Unacceptable Practices
• Submit a valid Signature Attestation with any documentation that lacks the rendering provider's signature. Do not resubmit altered documentation with a late-added provider signature. This will not be accepted by medical review. For an example of a signature attestation, refer to the article Medicare Medical Records: Signature Requirements, Acceptable and Unacceptable Practices located on our website.
   

NODOC — Documentation Requested for This Date of Service Was Not Received or Was Incomplete (Therefore we are unable to make a reasonable and necessary determination as defined under Section 1862(A) (1) (A) of The Act for the service billed, and this service has been denied)

• Submit all documentation related to the services billed within 45 days of the date on the ADR letter
• Review documentation prior to submission to ensure that the documentation is complete and that all dates of service requested are included
• Include any additional information pertinent to the date of service requested to support the services billed. For example: original chart notes, diagnostic, radiological or laboratory results.
• For claims denied with a M127 or N29 code listed on the remittance advice, be sure to submit all documentation for all dates of service on that claim with a reopen/redetermination request form by fax to JM Part B (803) 699–2427, JJ Part B (803) 870–0139, or RRB Appeals (803) 462–2218.
   

The Next Steps
The service-specific targeted medical review edits for Drugs & Biological Services: HCPCS Code J2778 – Ranibizumab (Lucentis) in North Carolina, South Carolina, Virginia and West Virginia will be continued based on moderate charge denial rates and medium to high impact severity errors. If significant billing aberrancies are identified, provider-specific review may be initiated.

If you are dissatisfied with a claim determination you have the right to request an appeal. Palmetto GBA encourages you to review the documentation originally submitted, and if you believe you have additional supporting documentation you may include this information with your appeal. For more information related to the appeals process please refer to the JM Redetermination: 1st Level Appeal form (PDF, 223 KB). Questions regarding this medical review can be directed to the Palmetto GBA Provider Contact Center at 855–696–0705.